Transplantation is the definitive treatment of end-stage organ disease. As the shortage of suitable organs poses its main limitation, the active management of potential organ donors becomes increasingly more important. The majority of solid organs are still obtained from donors after confirmed brain death. Brain death is the complete and irreversible cessation of all brain functions, and triggers a variety of severe pathophysiological changes in cardiovascular, hormonal and metabolic status that can result in organ damage. Moreover, brain death is associated with massive inflammatory response with a cytokine storm and complement activation that increases graft immunogenicity and adversely affects graft survival. Organs from brain-dead donors are more prone to graft dysfunction and rejection when compared to organs obtained from living donors. Brain death is thus believed to be an important risk factor influencing the quality of organs before procurement.
Background and Aims Hemoadsorption with Cytosorb® cartridge is one of extracorporeal blood purification therapies increasingly used in adult intensive care units in conditions with elevated inflammatory mediators. Many positive experiences of hemodynamic improvement of patients treated with hemoadsorption have resulted in attempts of its application also in critically ill pediatric patients. Here we present a case series of four children treated with hemoadsorption in pediatric intensive care unit (PICU) of University Medical Centre Ljubljana from September 2018 to January 2019. Method All patients were mechanically ventilated and required vasopressor and inotropic support. Hemoadsorption was used as a rescue therapy after all standard treatments for their underlying condition had been insufficient. CytoSorb® cartridge was coupled with continuous veno-venous hemodialysis (CVVHD, Prismaflex system, Gambro) in pre-filter (ST60 set, Gambro) position. In children <10 kg body weight (2 infants), the extracorporeal circuit was prefilled with a 1:1 mixture of packed red blood cells and saline, with heparin added. Automated regional citrate anticoagulation was used, blood flow was 30-100 ml/min and dialysate flow 500 ml/h. Results The youngest child was 10 days old 1.9 kg premature female with acute liver failure due to gestational alloimmune liver disease. CVVHD was started for hyperammonemia and concomitant CytoSorb® for severe hyperbilirubinemia (335 umol/l). Procedure was discontinued after 6 hours due to uncontrollable sepsis and hemodynamic collapse. We managed to normalize ammonia values and reduce bilirubin concentration (116 umol/l). Further treatment was withdrawn as a result of irreversible multiorgan failure. One month old 2.5 kg female patient was treated in PICU due to necrotizing enterocolitis and refractory septic shock with multiorgan failure. Oliguric acute kidney injury (AKI) required CVVHD and later on Cytosorb ® was added as an attempt to limit severe hyperinflammatory condition. During 19 hours of treatment the need for vasopressor support was increasing and metabolic acidosis was deepening. The patient required a short resuscitation a couple of hours into the procedure due to bradycardia which resulted in catheter and CVVHD circuit thrombosis. Dialysis was discontinued as urgent surgery was necessary. The patient later died of uncontrolled septic shock. Three years old 17 kg male was admitted with meningococcal septic shock, requiring initiation of veno-arterial ECMO. Cytosorb® with CVVHD was started and attached to the ECMO circuit. A significant decline of interleukine-6 (IL-6) was achieved without any procedure-related side effect and treatment was discontinued after 68 hours as patient's clinical status notably improved. The patient survived. Five years old 20 kg female patient, actively treated for acute lymphoblastic leukemia, was admitted with E. coli sepsis. Septic shock was unresponsive to conventional treatment therefore she was started on Cytosorb® with CVVHD as oliguric AKI also developed. Two consecutive procedures were preformed, the first for 31 and the second for 37 hours. Level of IL-6 decreased (from > 5000 ng/L to 1000 ng/L) and lactate level normalized. We achieved reduction in vasopressors and oxygen need during both procedures and patient's overall status greatly improved. Conclusion Although significantly increasing the volume of extracorporeal circuit, the use of Cytosorb® cartridge within CVVHD circuit is technically feasible even in critically ill children with low body weight, if principles of pediatric renal replacement therapy are considered. More efficacy and safety data on Cytosorb® utilization are necessary before inclusion in routine clinical practice. Treatment outcome is highly dependent on primary disease and severity of patient condition.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.